Preimplantation Genetic Testing Market: Growth, Size, Share, and Trends

The size of global preimplantation genetic testing market in terms of revenue was estimated to be worth $0.7 billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The growth in this market is attributed to the increasing demand for assisted reproductive technologies, rising maternal age trends, and ongoing research and development in the field of genetics. On the other hand, socio-ethical concerns surrounding preimplantation genetic testing may challenge the growth of market. Whereas, use of fertility treatment options by single parents and same-sex couples provides growth opportunities for market.

Attractive Opportunities in the Preimplantation Genetic Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Preimplantation Genetic Testing Dynamics

DRIVER: Declining fertility rate

Global fertility rates are observing a decline across a majority of the developed and several developing countries, owing to various factors such as increased maternal age of conceiving, low sperm count & motility, and hormonal imbalance, thereby leading to higher demand for IVF procedures. Moreover, with growing public awareness about the effective role of genetic techniques in the risk assessment of genetic disorders, the adoption of preimplantation genetic testing procedures is expected to grow during the forecast period. According to the World Health Organization (WHO), in 2020, approximately 8 million couples and 186 million individuals lived with infertility.

RESTRAINT: Alternative therapies and medications

The preimplantation genetic testing market is highly regulated, especially across the developed countries. For instance, in the U.S., service providers offering preimplantation genetic diagnosis & preimplantation genetic screening in IVF treatment have to adhere to mandatory regulations. Moreover, due to socio-ethical concerns related to embryo testing, a number of governments across the world are implementing stringent regulations, which is expected to negatively impact the growth of the preimplantation genetic diagnosis & preimplantation genetic screening market.

OPPORTUNITY: Use of fertility treatment options by single parents and same-sex couples

Regulations legalizing same-sex marriages in various countries across the globe, including Greenland, Ireland, Canada, South Africa, and the US, are further expected to increase the adoption of fertility procedures. The laws that support the use of IVF procedures by same-sex and single parents are as follows such as  The New South Wales Assisted Reproductive Technology Act 2007 permits all women, regardless of marital status, to access assisted conception procedures in the Australian state. On the other hand The Human Reproductive Technology Act 1991 allows all women (lesbian or single) to access donor insemination in Western Australia.

CHALLENGE: Socio-ethical concerns surrounding preimplantation genetic testing

Issues related to embryos and what to do with unused embryos are one of the major concerns related to the preimplantation genetic testing procedure. A number of couples fertilize as many eggs as they can during the treatment and freeze the remaining embryos for later use. Once the procedure is complete, several embryos remain unused, and clinics are reluctant to dispose of these unused embryos without the couples’ consent.

Preimplantation Genetic Testing Ecosystem

Prominent companies in this market include well-established, financially stable manufacturers of diagnostic and therapeutic preimplantation genetic testing. These companies have been operating in the market for several years and possess a diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in this market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), and The Cooper Companies, Inc. (US).

In 2022, reagents and consumables to observe highest growth rate of the preimplantation genetic testing industry, by product.

Based on the products, the global preimplantation genetic testing market is broadly segmented into instruments, reagents & consumables, and software & services. The expanding applications of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders) and increasing number of preimplantation genetic diagnosis & preimplantation genetic screening procedures being performed across the world’s major markets are driving the growth of the reagents and consumables segment.

In 2022, fertility centers segment to dominate the preimplantation genetic testing industry, by end user.

Based on end users, the preimplantation genetic testing market is segmented into hospitals, diagnostic labs, fertility clinics, and other end users. With declining fertility rates and the subsequent growth in the number of fertility centers, the number of infertility treatment procedures drives the demand for fertility centers market.

In 2022, North America to dominate in preimplantation genetic testing industry.

The global preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific and the Rest of the World. North America is expected to dominate during the forecast period, primarily due to the rising prevalence of polycystic ovary syndrome (PCOS), growing incidence of reproductive diseases such as chlamydia, and increasing age of first-time pregnancy.

To know about the assumptions considered for the study, download the pdf brochure

The preimplantation genetic testing market is dominated by players such Illumina (US), Thermo Fisher Scientific Inc (US), Agilent Technologies Inc (US), Revvity (US), and The Cooper Companies, Inc. (US).

Scope of the Preimplantation Genetic Testing Industry:

This research report categorizes the Preimplantation genetic testing market to forecast revenue and analyze trends in each of the following submarkets:

By Region

• North America
• Europe
• Asia Pacific
• Rest of the World

By Procedure Type

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Fluorescence In Situ Hybridization
• Comparative Genomic Hybridization
• Single-Nucleotide Polymorphism

By Product

• Reagents and Consumables
• Instruments
• Software and Services

By Application

• Aneuploidy
• Structural Chromosomal Abnormalities
• Single Gene Disorders
• X-Linked Disorders
• HLA Typing
• Gender Identification

By Type of Cycle

• Fresh Non-Donor
• Frozen Non-Donor
• Fresh Donor
• Frozen Donor

By End User

• Fertility Clinics
• Hospitals
• Diagnostic Laboratories
• Other End Users

Recent Developments of Preimplantation Genetic Testing Industry:

• In 2023, Thermo Fisher Scientific Inc. (US) launched two new NGS-based test kits to support preimplantation genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
• In 2022, The Cooper Companies, Inc. (US) released the addition of Parental QC, Genetic PN check, and Origin of Aneuploidy to PGT-A testing as PGT-Complete.
• In 2021, Vitrolife (Sweden) acquired Igenomix (Spain), a leader in reproductive genetic testing services primarily for IVF clinics.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst